GlaxoSmithKline Pharmaceuticals Limited (BOM:500660)

BOM:500660 Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 4, 2025	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	430,816	487,432	329,173	224,319	281,714	244,012
Market Cap Growth	5.42%	48.08%	46.74%	-20.37%	15.45%	15.67%
Enterprise Value	410,564	466,472	313,334	211,499	270,099	237,483
Last Close Price	2543.10	2840.33	1885.83	1256.53	1486.11	1262.72
PE Ratio	45.10	52.55	55.80	36.73	16.62	68.13
Forward PE	39.81	49.88	44.16	35.58	42.30	40.93
PS Ratio	11.62	13.00	9.53	6.90	8.59	8.34
PB Ratio	25.23	24.98	18.52	12.88	10.58	16.51
P/TBV Ratio	25.35	25.15	18.77	13.14	10.72	17.01
P/FCF Ratio	59.91	38.48	59.76	50.96	36.30	45.72
P/OCF Ratio	57.96	37.79	56.56	46.33	34.75	42.22
PEG Ratio	3.13	6.49	6.49	1.44	2.17	2.82
EV/Sales Ratio	11.07	12.44	9.07	6.50	8.24	8.12
EV/EBITDA Ratio	34.05	40.47	35.58	26.83	36.36	41.42
EV/EBIT Ratio	35.72	41.86	37.35	28.26	38.65	45.71
EV/FCF Ratio	57.10	36.82	56.89	48.05	34.80	44.50
Debt / Equity Ratio	0.02	0.01	0.01	0.01	0.01	0.02
Debt / EBITDA Ratio	0.03	0.01	0.02	0.02	0.03	0.06
Debt / FCF Ratio	0.05	0.01	0.03	0.04	0.03	0.07
Asset Turnover	1.00	0.98	1.00	0.82	0.85	0.94
Inventory Turnover	2.62	2.81	2.75	2.62	2.55	2.49
Quick Ratio	1.43	1.50	1.45	1.50	1.83	1.02
Current Ratio	1.78	1.79	1.84	1.88	2.18	1.63
Return on Equity (ROE)	56.52%	49.75%	33.53%	27.59%	18.39%	17.42%
Return on Assets (ROA)	19.39%	18.17%	15.24%	11.75%	11.28%	10.39%
Return on Capital (ROIC)	41.88%	37.07%	29.52%	21.07%	20.82%	19.24%
Return on Capital Employed (ROCE)	57.70%	50.60%	41.30%	37.40%	23.80%	29.50%
Earnings Yield	2.22%	1.90%	1.79%	2.72%	6.02%	1.47%
FCF Yield	1.67%	2.60%	1.67%	1.96%	2.76%	2.19%
Dividend Yield	1.65%	1.48%	1.70%	2.55%	2.02%	2.38%
Payout Ratio	96.18%	80.79%	91.80%	249.80%	29.89%	189.04%
Total Shareholder Return	1.67%	1.48%	1.70%	2.55%	2.02%	2.38%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.